Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (241-250 of 300) with videos related to

Pageof 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Leo I Gordon, Fangxin Hong, Richard I Fisher, et al.
Blood|March 13, 2016
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHLPaul M Barr, Gene B Saylors, Stephen E Spurgeon, et al.
Leukemia & Lymphoma|August 19, 2015
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomasBeata Holkova, Maciej Kmieciak, Prithviraj Bose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialRanjana H Advani, Fangxin Hong, Richard I Fisher, et al.
The New England Journal of Medicine|July 13, 2022
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's LymphomaStephen M Ansell, John Radford, Joseph M Connors, et al.
Blood|November 23, 2013
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraZheng Zhou, Laurie H Sehn, Alfred W Rademaker, et al.
Blood|April 2, 2020
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical TrialHeiko Schöder, Mei-Yin C Polley, Michael V Knopp, et al.
Blood|July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaPaul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.
Leukemia & Lymphoma|August 6, 2025
Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot studyMichael A Superdock, Lisa M Rimsza, Danielle S Wallace, et al.
Blood Advances|September 18, 2025
Development and validation of a gene expression signature to predict early events in patients with follicular lymphomaColleen A Ramsower, George Wright, Hongli Li, et al.
Pageof 30

Showing results (241-250 of 300) with videos related to

Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Leo I Gordon, Fangxin Hong, Richard I Fisher, et al.
Blood|March 13, 2016
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHLPaul M Barr, Gene B Saylors, Stephen E Spurgeon, et al.
Leukemia & Lymphoma|August 19, 2015
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomasBeata Holkova, Maciej Kmieciak, Prithviraj Bose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2015
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 TrialRanjana H Advani, Fangxin Hong, Richard I Fisher, et al.
The New England Journal of Medicine|July 13, 2022
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's LymphomaStephen M Ansell, John Radford, Joseph M Connors, et al.
Blood|November 23, 2013
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraZheng Zhou, Laurie H Sehn, Alfred W Rademaker, et al.
Blood|April 2, 2020
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical TrialHeiko Schöder, Mei-Yin C Polley, Michael V Knopp, et al.
Blood|July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaPaul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.
Leukemia & Lymphoma|August 6, 2025
Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot studyMichael A Superdock, Lisa M Rimsza, Danielle S Wallace, et al.
Blood Advances|September 18, 2025
Development and validation of a gene expression signature to predict early events in patients with follicular lymphomaColleen A Ramsower, George Wright, Hongli Li, et al.
Pageof 30